Drugs / TJO-083
last change Jun 2023 re-read 2 minutes ago

TJO-083

Developed for
dry eye syndrome
Investigated by
Taejoon Pharmaceutical Co., Ltd.

Trials 1 · a red edge is where a trial was stopped

20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT05346783 Oct 2021 → Dec 2022 dry eye syndrome Taejoon Pharmaceutical Co., Ltd. Unknown No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as TJO-083 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05346783